NCT02544997: A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: AR+, ER+, PR+
Other Mutations: EGFR, HER2, HER2-low
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have an activated HER2 mutation or EGFR mutation/gene amplification or activated AR pathway
Exclusions: No prior history of pan-HER TKI including poziotinib for MBC; Documented leptomeningeal brain metastasis; Known brain metastases unless treated and stable; Patients with HER2+ breast cancer

Comments are closed.

Up ↑